2种不同复方降压制剂24h控制原发性高血压的疗效比较

Coaprovel vs.Hyzaar for 24 h Ambulatory Blood Pressure in Patients with Essential Hypertension

目的:比较2种不同血管紧张素Ⅱ受体拮抗药和利尿药组合的复方降压制剂的降压疗效及安全性。方法:选择48例原发性高血压患者,随机分成2组(安博诺组和海捷亚组),每天各1片,治疗4wk,观察诊室血压的降压疗效及动态血压监测的有关指标。结果:2组治疗后诊室血压显示:安博诺组2wk与4wk总有效率分别高于海捷亚组(P<0.05)。动态血压监测显示:2组治疗用药后24h平均收缩压(SBP)和舒张压(DBP)均较治疗前显著降低(P<0.01);2组治疗后白天及夜间血压负荷值均有降低(P<0.01);安博诺组治疗用药后24h平均SBP和DBP、白天及夜间血压负荷值下降较海捷亚组降低更明显(P<0.05);2组治疗后4wkSBP和DBP昼夜下降百分率均显著提高(P<0.01),组间比较无差异(P>0.05);2组不良反应发生率比较差异无统计学意义(P>0.05)。结论:2组降压疗效明确,安博诺组降压幅度高于海捷亚组,对昼夜节律异常均有改善作用。2组不良反应发生率低,耐受性好。

OBJECTIVE： To evaluate the antihypertensive efficacy and safety of two different Angiotensin Ⅱ receptor antagonists in combination with diuretics respectively for patients with essential hypertension.METHODS： A total of 48 patients with essential hypertension were enrolled and randomly assigned to Coaprovel group（Irbesartan and Hydrochlorothiazide tablets） or Hyzaar group（Losartan and Hydrochlorothiazide tablets） at a dose of 1 tablet daily for 4wk.The major outcome measures were antihypertensive efficacy and dynamic blood pressure monitoring indexes.RESULTS： After 2-week and 4- week treatment, the total effective rates for hypertension in Coaprovel group were higher than in Hyzaar group（P 〈 0.05） .The ambulatory blood pressure monitoring results demonstrated： the average 24h systolic blood pressure（SBP） and diastolic blood pressure（DBP） in two groups were significant decreased after treatment as compared before treatment（P 〈 0.01） .Both daytime and nighttime blood pressure loading values were decreased in both groups after treatment（P〈 0.01） .The average 24h SBP and DBP and both daytime and nighttime blood pressure loading values in Coaprovel group were significantly lower than in Hyzaar group after treatment（P 〈 0.05） .After 4-week treatment, the descending percentage of SBP and DBP in day and night were significantly elevated in both group（P〈 0.01）,with no difference between the two groups（P 〉0.05） .The incidences of adverse effect in two groups were not statistically significant（P 〉0.05） .CONCLUSION：Both group showed approved antihypertensive efficacy, with Coaprovel group showing higher efficacy than in Hyzaar group; and both group showed improvement in allorhythmia.Both group showed low incidences of adverse effect but good tolerance.